Connect with us

Economy

Philips, Masimo Sign Deal On Patient Monitoring, Select Therapy Solutions

Published

on

philips masimo

By Dipo Olowookere

A multi-year business partnership agreement has been sealed between Philips and Masimo Corporation focused on innovations in patient monitoring and therapy solutions.

The partnership, Business Post leant, includes joint marketing and sales programs in North America and certain markets in Asia and Europe for Masimo’s non-invasive sensor technologies, such as its rainbow and SET platforms, in conjunction with Philips’ patient monitoring and select therapy solutions.

In addition, Philips will in the future integrate Masimo SedLine brain function monitoring, O3 regional oximetry, and Nomoline capnography technologies in certain Philips IntelliVue monitors.

Philips is a global leader in patient monitoring solutions with a comprehensive product portfolio ranging from multi-parameter bedside monitors to wearable patient monitors combined with mobile applications and clinical decision support tools.

With a primary focus on prediction and prevention of patient deterioration, these integrated solutions aim to support clinical workflow and caregiver efficiencies, and enhance patient care. In 2015, an estimated 275 million patients were monitored using Philips’ patient monitoring solutions.

Sensor and signal processing technologies are an essential component of patient monitoring solutions, and Masimo is a prolific innovator in this field. Examples of Masimo’s non-invasive sensor and signal processing technology innovations include Masimo SET pulse oximetry, Masimo rainbow Pulse CO-Oximetry and Masimo total hemoglobin (SpHb) monitoring technology.

“This business partnership agreement marks an important day for us and our customers as two leaders in patient monitoring collaborate to develop solutions designed to enhance clinical outcomes and patient safety,” said Frans van Houten, CEO of Royal Philips. “I am very satisfied that we have reached an agreement that is beneficial for both companies and that we have ended our legal disputes. Going forward, Philips and Masimo will completely focus on jointly delivering meaningful innovations to our customers, such as the integration of Masimo rainbow technology across our IntelliVue patient monitoring product range.”

“It’s wonderful to think that Masimo and Philips will be working together for the benefit of patients and clinicians around the world,” said Joe Kiani, Chairman and CEO of Masimo. “I am delighted that we were able to reach this important agreement which allows us to focus on the future to deliver the solutions that our customers have been looking for.”

In conjunction with the appropriate Philips patient monitoring platform, Masimo’s rainbow SET technology analyzes multiple wavelengths of light to accurately measure total hemoglobin (SpHb), oxygen content (SpOC), carboxyhemoglobin (SpCO), methemoglobin (SpMet) and Pleth Variability Index (PVI) non-invasively and continuously. Continuous monitoring of SpHb on a Philips monitor at the point of care provides clinicians with real-time visibility to changes in hemoglobin in between invasive blood samplings.

Anticipated cash flow and income consequences for Philips

As part of the business partnership agreement, Philips and Masimo have agreed to end all pending lawsuits between the two companies, which includes that Philips is released from paying the $467 million jury verdict that was awarded to Masimo in October, 2014.

Philips has agreed to make a $300 million cash payment to Masimo in the fourth quarter of 2016; and to invest in the relationship by making certain marketing and product integration commitments over the coming years. Entering into the business partnership agreement has minimal impact on income from operations (EBIT) in the fourth quarter of 2016.

Anticipated cash flow and income consequences for Masimo

As the result of anticipated legal fee savings during the fourth fiscal quarter, Masimo now expects its fiscal 2016 GAAP earnings per diluted share, exclusive of the impact of the business partnership agreement, to be $2.14, up from $2.13.

Masimo expects to use some of the after-tax proceeds from the business partnership agreement to repay amounts outstanding under its revolving line of credit. The guidance set forth above is an estimate only and actual performance could differ.

Dipo Olowookere is a journalist based in Nigeria that has passion for reporting business news stories. At his leisure time, he watches football and supports 3SC of Ibadan. Mr Olowookere can be reached via [email protected]

Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Economy

Why Transparency Matters in Your Choice of a Financial Broker

Published

on

HFM financial broker

Choosing a Forex broker is essentially picking a partner to hold the wallet. In 2026, the market is flooded with flashy ads promising massive leverage and “zero fees,” but most of that is just noise. Real transparency is becoming a rare commodity. It isn’t just a corporate buzzword; it’s the only way a trader can be sure they aren’t playing against a stacked deck. If a broker’s operations are a black box, the trader is flying blind, which is a guaranteed way to blow an account.

The Scam of “Zero Commissions”

The first place transparency falls apart is in the pricing. Many brokers scream about “zero commissions” to get people through the door, but they aren’t running a charity. If they aren’t charging a flat fee, they are almost certainly hiding their profit in bloated spreads or “slippage.” A trader might hit buy at one price and get filled at a significantly worse one without any explanation. This acts as a silent tax on every trade. A transparent broker doesn’t hide the bill; they provide a live, auditable breakdown of costs so the trader can actually calculate their edge.

The Conflict of Market Making

It is vital to know who is on the other side of the screen. Many brokers act as “Market Makers,” which is a polite way of saying they win when the trader loses. This creates a massive conflict of interest. There is little incentive for a broker to provide fast execution if a client’s profit hurts their own bottom line. A broker with nothing to hide is open about using an ECN or STP model, simply passing orders to the big banks and taking a small, visible fee. If a broker refuses to disclose their execution model, they are likely betting against their own clients.

Regulation as a Safety Net

Transparency is worthless without an actual watchdog. A broker that values its reputation leads with its licenses from heavy-hitters like the FCA or ASIC. They don’t bury their regulatory status in the fine print or hide behind “offshore” jurisdictions with zero oversight. More importantly, they provide proof that client funds are kept in segregated accounts. This ensures that if the broker goes bust, the money doesn’t go to their creditors—it stays with the trader. Without this level of openness, capital is essentially unprotected.

The Withdrawal Litmus Test

The ultimate test of a broker’s transparency is how they handle the exit. There are countless horror stories of traders growing an account only to find that “technical errors” or vague “bonus terms” prevent them from withdrawing their money. A legitimate broker has clear, public rules for getting funds out and doesn’t hide behind a wall of unreturned emails. If a platform makes it difficult to see the exit strategy, it’s a sign that the front door should have stayed closed.

Conclusion

In 2026, honesty is the most valuable feature a broker can offer. It is the foundation that allows a trader to focus on the charts instead of worrying if their stops are being hunted. Finding a partner with clear pricing, honest execution, and real regulation is the first trade that has to be won. Flashy marketing is easy to find, but transparency is what actually keeps a trader in the game for the long haul.

Continue Reading

Economy

Nigeria’s Stock Market Indices Shrink 0.41% Amid Panic Sell-Offs

Published

on

stock market indices

By Dipo Olowookere

The Nigerian Exchange (NGX) Limited came under panic sell-offs on Thursday, as the investing community awaits the outcome of a probe into trading activities around one of the stocks on the bourse.

On Monday, trading in Zichis equities was prohibited by the regulator after it gained almost 900 per cent in one month of being listed by introduction on the growth board of the exchange.

This action triggered cautious trading on Customs Street, and things have not remained the same since then.

Yesterday, the key performance indices of the Nigerian bourse further depreciated by 0.41 per cent, the third straight loss this week, as investors book profit before being trapped.

It was observed that the energy industry gained 0.12 per cent and was the only one in green, as the industrial goods space shed 1.19 per cent, the banking counter depreciated by 0.63 per cent, the insurance sector lost 0.32 per cent, and the consumer goods segment tumbled by 0.03 per cent.

As a result, the All-Share Index (ASI) contracted by 802.39 points to 193,567.81 points from 194,370.20 points, and the market capitalisation decreased by N515 billion to N124.239 trillion from N124.754 trillion.

During the session, investors traded 868.5 million shares worth N31.5 billion in 69,310 deals compared with the 1.4 billion shares valued at N46.2 billion exchanged in 70,222 deals at midweek, showing a drop in the trading volume, value, and number of deals by 37.96 per cent, 31.82 per cent, and 1.30 per cent, respectively.

Jaiz Bank led the activity chart with 78.9 million equities valued at N1.2 billion, Japaul traded 73.3 million stocks worth N274.8 million, Access Holdings exchanged 66.9 million shares for N1.7 billion, Chams sold 56.9 million equities worth N239.6 million, and Zenith Bank transacted 45.5 million stocks valued at N4.1 billion.

The worst-performing stock for the day was Jaiz Bank after it lost 9.98 per cent to trade at N12.63, Ikeja Hotel declined by 9.90 per cent to N37.75, John Holt shrank by 9.90 per cent to N8.65, Enamelware slipped by 9.88 per cent to N36.50, and Cadbury went down by 9.69 per cent to N61.95.

On the flip side, FTN Cocoa was the best-performing stock after it gained 10.00 per cent to sell for N6.05, RT Briscoe improved by 9.95 per cent to N11.38, Deap Capital soared 9.92 per cent to N6.98, Japaul grew by 9.91 per cent to N3.77, and Ellah Lakes surged 9.72 per cent to N11.85.

Investor sentiment remained bearish as the exchange finished with 30 price gainers and 38 price losers, implying a negative market breadth index.

Continue Reading

Economy

Champion Breweries Concludes Bullet Brand Portfolio Acquisition

Published

on

bullet energy drink champion breweries

By Aduragbemi Omiyale

The acquisition of the Bullet brand portfolio from Sun Mark has been completed by Champion Breweries Plc, a statement from the company confirms.

This marks a transformative milestone in the organisation’s strategic expansion into a diversified, pan-African beverage platform.

With this development, Champion Breweries now owns the Bullet brand assets, trademarks, formulations, and commercial rights globally through an asset carve-out structure.

The assets are held in a newly incorporated entity in the Netherlands, in which Champion Breweries holds a majority interest, while Vinar N.V., the majority shareholder of Sun Mark, retains a minority stake.

Bullet products are currently distributed in 14 African markets, positioning Champion Breweries to scale beyond Nigeria in the high-growth ready-to-drink (RTD) alcoholic and energy drink segments.

This expansion significantly broadens the brewer’s addressable market and strengthens its revenue base with an established, profitable portfolio that already enjoys strong brand recognition and consumer loyalty across multiple markets.

“The successful completion of our public equity raises, together with the formal close of the Bullet acquisition, marks a defining moment for Champion Breweries.

“The support we received from both existing shareholders and new investors reflects strong confidence in our long-term strategy to build a diversified, high-growth beverage platform with pan-African scale.

“Our focus now is on disciplined execution, integration, and delivering sustained value across markets,” the chairman of Champion Breweries, Mr Imo-Abasi Jacob, stated.

Through this transaction, Champion Breweries is expected to achieve enhanced foreign exchange earnings, expanded distribution leverage across African markets, integrated supply chain efficiencies, portfolio diversification into high‑growth consumer beverage categories, and strengthened presence in the RTD and energy drink segments.

The acquisition accelerates Champion Breweries’ transition from a regional brewing business to a multi-category consumer platform with continental reach.

Bullet Black is Nigeria’s leading ready-to-drink alcoholic beverage, while Bullet Blue has built a strong presence in the energy drink category across several African markets.

Continue Reading

Trending